Novel Streptococcus salivarius strain KCCM13161P having antibacterial, antifungal, anti-inflammatory and caries-inhibiting activities and oral composition containing the same
The novel Streptococcus salivarius G7 strain offers enhanced antibacterial, antifungal, and anti-inflammatory properties, effectively preventing and improving oral diseases by inhibiting pathogenic bacteria and fungi, and reducing inflammation and bad breath.
Patent Information
- Application Number
- JP2023118547
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2023-03-23
- Filing Date
- 2023-07-20
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-07-20
AI Technical Summary
There is an urgent need for oral probiotics with broad antibacterial activity to maintain microbial balance and prevent oral diseases such as gingivitis, periodontitis, dental caries, and fungal infections like candidiasis, while also addressing systemic health issues.
A novel Streptococcus salivarius strain (S. salivarius G7, KCCM13161P) with enhanced antibacterial, antifungal, and anti-inflammatory properties is developed, effective against a range of pathogenic bacteria and fungi, including Aggregatibacter actinomycetemcomitans, Candida albicans, and others, and formulated into various oral compositions.
The S. salivarius G7 strain demonstrates twice the antibacterial effect compared to conventional strains, significantly inhibits pathogen growth, reduces inflammation, and suppresses volatile sulfur compounds to alleviate bad breath, effectively preventing and improving oral diseases.
Smart Images

Figure 0007580829000005 
Figure 0007580829000006 
Figure 0007580829000007
Abstract
Description
[Technical field]
[0001] The present invention relates to a novel Streptococcus salivarius strain having antibacterial, antifungal, anti-inflammatory and caries-inhibiting activities, and an oral composition containing the same. [Background technology]
[0002] Oral infectious diseases can be divided into gingival and dental diseases, and these infectious diseases are related to biofilms formed by various types of bacteria. In healthy people, biofilms are formed in balance by various types of bacteria with a high ratio of symbiotic bacteria. However, when this balance is disrupted and certain bacteria proliferate, it can lead to oral diseases.
[0003] Actinomyces israelii and Actinomyces naeslundii are typical gingivitis-causing bacteria, while Streptococcus mutans and Streptococcus sobrinus are known as dental cariogenic bacteria (Howell A. et al., 1962; Loesche WJ. et al., 1978). These bacteria have the characteristics of acidogenesis and aciduricity, and induce dental caries (Conrads G et al., 2014). In addition, Enterococcus faecalis is the predominant species of human enterococci, and is involved in oral diseases such as root canal infection, periodontitis, and peri-implantitis due to its antibiotic resistance characteristics (Dahlen G., et al., 1993; Rams TE., et al., 2013). (Non-Patent Documents 1-5)
[0004] On the other hand, some strains can be used as probiotics for oral use (Li X., 2021; Hale JDF., et al., 2022). These bacteria produce bacteriocin to suppress surrounding bacteria during the process of competing for habitat with other bacteria. Streptococcus salivarius also produces various lantibiotics such as salivaricin A, salivaricin B, salivaricin 9, and salivaricin G3216-18, which are similar to bacteriocins (Wescombe PA., et al., 2006). Streptococcus salivarius is a gram-positive facultative anaerobic bacterium that acts as a symbiotic bacterium living on the surface of human mucous membranes (Aas JA., et al., 2005) and plays an important ecological role in forming a barrier against pathogens and reducing adhesion and colonization (Wescombe PA., et al., 2006). Therefore, the possibility of using it as an oral probiotic has been steadily raised (Non-Patent Documents 6-10).
[0005] In recent years, various research papers have published results showing that harmful bacteria present in the oral cavity have a negative impact on systemic diseases (lupus, systemic sclerosis, inflammatory bowel disease, dementia, etc.), and the concept has been expanded to say that maintaining microbial balance in the oral cavity can affect not only dental health but also systemic health.
[0006] It is generally known that systemic diseases occur due to the imbalance of normal bacterial flora in the human body or the invasion and proliferation of foreign microorganisms. Therefore, rather than using antibiotics that suppress the growth of microorganisms, the use of oral probiotics that have antibacterial effects while maintaining the microbial ecosystem may be more useful in promoting public health.
[0007] For this reason, the development of oral probiotics with broad antibacterial activity is urgently needed. [Prior art documents] [Patent documents]
[0008] [Patent Document 1] Korean Patent Publication No. 10-2022-0139280, Oral composition containing a novel Lactobacillus plantarum strain, October 14, 2022. Published. [Patent Document 2] Korean Patent Registered No. October 14, 2022, Composition for improving, preventing or treating bad breath or tooth decay containing Lactobacillus fermentum OK strain derived from the human oral cavity, December 29, 2020. Registered. [Patent Document 3] Korean Patent Publication No. 10-2023-0017372, Composition containing superoxide dismutase and / or Bacillus strain spores and its use for improving oral health, February 3, 2023. Published. [Patent Document 4] Korean Patent Registered No. 2023-02-03, Composition for improving, preventing or treating bad breath or tooth decay containing Lactobacillus gasseri HHuMIN D derived from the human oral cavity, December 29, 2020. Registered. [Non-patent literature]
[0009] [Non-Patent Document 1] Howell A, Stephan RM, Paul F. Prevalence of Actin-omyces israelii, A. naeslundii, Bacterionema matruchotii, and Candida albicans in selected areas of the oral cavity and saliva. J Dent Res 1962;41:1050-1059. [Non-Patent Document 2] Loesche WJ,Syed SA.Bacteriology of human experimental gingivitis:effect of plaque and gingivitis score.Infect Immun1978;21:830-839.
Table 3
Fashion 4
Wood 5
Wood 6
Waterfall 7
Fashion 8
[0010] An object of the present invention is to provide a novel Streptococcus salivarius strain having high antibacterial, antifungal and anti-inflammatory effects, and an oral composition containing the same. [Means for solving the problem]
[0011] In order to solve the above problems, the present invention provides a novel Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain having antibacterial, antifungal and anti-inflammatory activities.
[0012] The antibacterial activity was demonstrated against Aggregatibacter actinomycetemcomitans, Actinomyces israelii, Actinomyces naeslundii, Enterococcus faecalis, Fusobacterium nucleatum, Porphyromonas gingivalis, Prevotella intermedia, Bacteroides intermedius, Prevotella nigrescens, Streptococcus mutans, Streptococcus sobrinus, Streptococcus pneumoniae, and Streptococcus pneumoniae. The antibacterial activity includes, but is not limited to, antibacterial activity against one or more selected from the group consisting of Pneumoniae, Streptococcus pyogenes, Actinomyces viscosus, Escherichia coli, and Staphylococcus aureus.
[0013] In the present invention, "Aggregatibacter actinomycetemcomitans" is one of the representative gingivitis-inducing bacteria, and is a Gram-negative, facultative anaerobic, non-motile bacterium associated with locally aggressive periodontitis. A. actinomycetemcomitans rarely causes non-oral infections such as endocarditis, and produces exotoxins leukotoxin (LT) and cytolethal distending toxin (Cdt). The exotoxin LT inhibits immunity by forming holes in the plasma membrane of monocytes, neutrophils, and some lymphocytes, damaging the cells, and Cdt is a DNA degrading enzyme that inhibits cell division of various cells including epithelial cells, gingival fibroblasts, and lymphocytes, and induces apoptosis in some cells in which cell division is inhibited. As an endotoxin, it secretes lipopolysaccharide (LPS), which induces the production of proinflammatory cytokines (IL-1, TNF) by macrophages, and induces bone resorption and destruction of gelatinous matrix.
[0014] In the present invention, "Actinomyces israelii" is an opportunistic pathogenic bacterium that coexists in the vagina, colon, and mouth of normal humans and causes infectious diseases when the individual's immune system is weakened, inducing gingivitis. Actinomycosis is most commonly caused by A. israelii and can be treated with antibiotics.
[0015] In the present invention, "Actinomyces naeslundii" is a gram-positive rod-shaped bacterium found in the human mouth and in women with bacterial vaginosis, and is associated with various periodontal diseases including dental caries, and is particularly prone to inducing gingivitis. A. naeslundii can also cause actinomycosis, forming abscesses that can secrete edema and pus, and may be accompanied by tissue fibrosis. A. naeslundii often infects the mouth, face, and neck, but can also rarely infect the chest, abdomen, pelvis, and central nervous system.
[0016] In the present invention, "Enterococcus faecalis" is a gram-positive, symbiotic bacterium that inhabits the gastrointestinal tract of humans and other mammals, and is one of the representative bacteria that induce periapical inflammation. It is generally found in the range of 30-90% of teeth that have undergone root canal treatment, and it is known that reinfected teeth that have undergone root canal treatment are about 9 times more likely to carry E. faecalis than those with primary infection. In rare cases, it can induce endocarditis, septicemia, urinary tract infection (UTI), meningitis, and other human infections, and is known to have multi-drug resistance (MDR) that shows resistance to commonly used antibacterial agents such as aminoglycosides, aztreonam, cephalosporins, clindamycin, semi-synthetic penicillins nafcillin and oxacillin, and trimethoprim / sulfamethoxazole.
[0017] In the present invention, "Fusobacterium nucleatum" is a Gram-negative bacterium that coexists in the human oral cavity, and is one of the representative bacteria that induce periodontitis. It is a major component of periodontal plaque due to its ability to aggregate with other bacterial species in the oral cavity. Many other studies have also demonstrated its association with premature birth and colorectal cancer.
[0018] In the present invention, "Porphyromonas gingivalis" is a non-motile, gram-negative, rod-shaped, anaerobic, pathogenic bacterium, and a representative periodontitis-inducing bacterium. P. gingivalis is found in the oral cavity, upper gastrointestinal tract, respiratory tract, and colon with periodontitis, and is known to be associated with Alzheimer's disease and rheumatoid arthritis.
[0019] In the present invention, "Prevotella intermedia (Bacteroides intermedius)" is a gram-negative obligate anaerobic pathogenic bacterium involved in periodontal infections including gingivitis and periodontitis, and is often found in acute necrotizing ulcerative gingivitis. P. intermedia uses steroid hormones as growth factors and is relatively common in pregnant women, and is also isolated from women with bacterial vaginosis.
[0020] In the present invention, "Prevotella nigrescens" is a Gram-negative bacterium that is a part of the normal oral flora and is one of the bacteria that induces opportunistic periodontitis. It is known to be associated with nasopharyngeal and intraperitoneal infections and carotid atherosclerosis in addition to periodontal disease.
[0021] In the present invention, "Actinomyces viscosus" is a gram-positive, facultative anaerobic bacterium that inhabits the mouths of 70% of adults. A. viscosus causes periodontal disease in animals, and can cause endocarditis in humans as well as tartar and root surface caries, and in very rare cases, can cause pulmonary infections.
[0022] In the present invention, 'Streptococcus mutans' is also known as dental caries bacteria, and is the main causative bacterium of dental caries together with Lactobacillus. S. mutans induces dental caries, discoloring the teeth to black and causing dental caries.
[0023] In the present invention, "Streptococcus sobrinus" is a gram-positive, non-motile, anaerobic bacterium that promotes intradental caries formation by combining with S. mutans. In particular, S. sobrinus is known to be more closely related to the prevalence of dental caries than S. mutans.
[0024] In the present invention, "Streptococcus pneumoniae" is a type of streptococcus that is gram-positive and hemolytic. Although it does not cause symptoms in healthy people, it is the main cause of pneumonia and meningitis in children and elderly people with weak immune systems, and induces upper respiratory tract diseases.
[0025] In the present invention, "Streptococcus pyogenes" is a pyogenic streptococcus, a gram-positive aerobic bacterium. S. pyogenes inhabits the throat, genital mucosa, rectum and skin and can cause various diseases such as streptococcal pharyngitis, rheumatic fever, rheumatic heart disease and scarlet fever, and induces upper respiratory tract diseases.
[0026] In the present invention, "Escherichia coli" is a representative gram-negative pathogenic bacterium, which can be contracted by eating food containing E. coli or by touching an animal infected with E. coli, and can cause abdominal cramps, nausea, vomiting, etc.
[0027] In the present invention, "Staphylococcus aureus" is a representative gram-positive pathogenic bacterium, which is a causative bacterium of purulent diseases and food poisoning. S. aureus is present in the nose, respiratory system, and skin, and food poisoning caused by S. aureus is a toxin-type food poisoning that occurs when the toxins produced by the bacteria as they grow in food are ingested.
[0028] In the present invention, the antifungal activity is, but is not limited to, antifungal activity against Candida albicans.
[0029] In the present invention, "Candida albicans" is an opportunistic pathogenic fungus, which is a common member of the human intestinal flora. It is found in the gastrointestinal tract and mouth in 40-60% of healthy adults, but becomes pathogenic in immune-compromised individuals and causes candidiasis. Candidiasis is the third or fourth most frequent pathogenic infection worldwide, and in particular, it can cause infection of the skin and genitals as well as the oral cavity and esophagus, and systemic infection is treated with amphotericin B, echinocandin, fluconazole, etc.
[0030] The novel Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain of the present invention has an antibacterial effect that is 4 to 8 times higher than that of conventional Streptococcus salivarius K12 and Streptococcus salivarius (Streptococcus salivarius ATCC7073 (type strain)).
[0031] The novel Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain of the present invention has a higher effect of suppressing bad breath than the conventional Streptococcus salivarius K12 and Streptococcus salivarius (Streptococcus salivarius ATCC7073 (type strain)). The S. salivarius G7 (accession number KCCM13161P) culture solution of the present invention can significantly suppress bad breath caused by oral diseases by reducing the concentrations of hydrogen sulfide (HS) and methyl sulfide (CHSH), which are volatile sulfur compounds that induce bad breath in P. gingivalis culture solutions.
[0032] The present invention provides a composition for preventing or improving oral diseases, comprising one or more of the novel Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain having the antibacterial, antifungal, and anti-inflammatory activities; a disruptant thereof; a concentrate thereof; a dried product thereof; a culture thereof; an extract thereof; a heat-treated culture dried product thereof; and a fraction thereof.
[0033] The oral disease may be one or more selected from the group consisting of gingivitis, periodontitis, dental caries, halitosis, sensitive teeth, oral candidiasis, upper respiratory tract disease, and periapical disease, but is not limited thereto.
[0034] The oral diseases may be caused by infection with pathogenic bacteria or fungi in the oral cavity or upper respiratory tract, and the composition of the present invention can prevent or improve the oral diseases by its antibacterial and anti-inflammatory activities.
[0035] The composition for preventing or improving oral diseases may be formulated into one product selected from the group consisting of toothpaste, mouthwash, gum, candy, caramel, jellies, oral spray, oral ointment, mouthwash, oral cleaning agent, and tooth whitening agent, but is not limited thereto.
[0036] The present invention provides a probiotic composition for oral use, comprising the novel Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain having antibacterial, antifungal and anti-inflammatory activities or a culture thereof, the probiotic composition for oral use being in one or more dosage forms selected from the group consisting of tablets, capsules, pills, granules, liquids, powders, pieces, pastes, syrups, gels, jellies, gums and candies, but is not limited thereto. The carrier, excipient and diluent that may be included in the probiotics include lactose, dextrose, maltodextrin, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.When formulating, diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, sweeteners, and acidulants can be used.
[0037] The present invention provides a pharmaceutical composition for preventing or treating oral diseases, comprising one or more of the novel Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain having the antibacterial, antifungal and anti-inflammatory activities; its homogenate; its concentrate; its dried product; its culture; its extract; its heat-treated culture dried product; and its fraction.
[0038] The oral disease may be at least one selected from the group consisting of gingivitis, periodontitis, dental caries, halitosis, sensitive teeth, oral candidiasis, upper respiratory tract disease, and periapical disease.
[0039] The novel Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain, its disruption product, its concentrate, its dry product, its culture product, its extract, its heat-treated culture dry product, and its fraction may be added in an amount of preferably 0.001-50% by weight, more preferably 0.001-40% by weight, and most preferably 0.001-30% by weight, based on the total weight of the entire pharmaceutical composition.
[0040] The pharmaceutical compositions may be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, liquids, aerosols, and external preparations by a conventional method. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations can be prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
[0041] The dosage of the pharmaceutical composition of the invention may vary depending on the age, sex, and weight of the subject to be treated, the particular disease or pathological condition being treated, the severity of the disease or pathological condition, the route of administration, and the judgment of the prescriber, and determination of the dosage based on such factors is within the level of skill in the art. Generally, dosages range from 1×10 6 CFU / day ~ approx. 1×10 11 CFU / day. The preferred dosage is 1×10 8 CFU / day ~1×10 11 CFU / day, and a more preferred dose is 1×10 8 CFU / day ~1×10 10 CFU / day. The dosage may be once a day or in several divided doses. The dosage is not intended to limit the scope of the present invention in any way. The pharmaceutical composition of the present invention may be administered to mammals such as mice, livestock, and humans by various routes.
[0042] The composition provides a health functional food for preventing or improving oral diseases, comprising one or more of the novel Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain having the antibacterial, antifungal, and anti-inflammatory activities; its disruption; its concentrate; its dried product; its culture; its extract; its heat-treated culture dried product; and its fraction.
[0043] The health functional food may contain one or more of the novel Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain having antibacterial, antifungal and anti-inflammatory activities; its disruption; its concentrate; its dried product; its culture; its extract; its heat-treated culture dried product; and its fraction, preferably in an amount of 0.001 to 50% by weight, more preferably 0.001 to 30% by weight, and most preferably 0.001 to 10% by weight based on the total weight of the entire food.
[0044] The health functional foods include forms such as tablets, capsules, powders, pills, and liquids, and foods to which the extract of the present invention can be added include, for example, various foods, beverages, gums, teas, vitamin complexes, health functional foods, etc. Effect of the Invention
[0045] The present invention relates to a novel Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain having antibacterial, antifungal and anti-inflammatory activities, and a composition for preventing or improving oral diseases and oral probiotics containing the same. Specifically, the novel Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain has strong antibacterial and anti-inflammatory activities against strains that induce periodontal disease, thereby preventing, treating and improving periodontal disease, and suppressing bad breath caused by oral diseases, thereby contributing to improving oral health. [Brief description of the drawings]
[0046] [Figure 1]FIG. 1 shows the Streptococcus salivarius G7 (deposition number KCCM13161P) 16S rRNA sequence (SEQ ID NO:1). [Diagram 2] FIG. 1 shows a phylogenetic diagram of Streptococcus salivarius G7 (deposition number KCCM13161P). [Diagram 3] These are the results of an experiment on the antibacterial activity of Streptococcus salivarius G7 (accession number KCCM13161P) against gingivitis-inducing bacteria A. actinomycetemcomitans, A. israelii, A. naeslundii, and apical inflammation-inducing bacteria E. faecalis. [Figure 4] These are the results of an experiment on the antibacterial activity of Streptococcus salivarius G7 (accession number KCCM13161P) against periodontitis-inducing bacteria F. nucleatum, P. gingivalis, P. intermedia, and P. nigrescens. [Diagram 5] These are the results of an experiment on the antibacterial activity of Streptococcus salivarius G7 (accession number KCCM13161P) against dental caries-inducing bacteria A. viscosus, S. mutans, and S. sobrinus, and upper respiratory tract disease-inducing bacteria S. pneumoniae and S. pyogenes. [Figure 6] 1 shows the results of an antibacterial experiment of Streptococcus salivarius G7 (accession number KCCM13161P) against the representative gram-negative pathogen E. coli and the gram-positive pathogen S. aureus. [Figure 7] These are the results of an experiment on the antifungal activity of Streptococcus salivarius G7 (accession number KCCM13161P) against C. albicans, a fungus that causes oral candidiasis. [Figure 8] The virulence of cell lysates containing cell surface material of S. salivarius G7 (Accession No. KCCM13161P) of the present invention was confirmed. A. TNF-α mRNA expression, B. IL-8 mRNA expression, C. TNF-α production, D. IL-8 production [Figure 9]Graph showing the effect of S. salivarius G7 (Accession No. KCCM13161P) LTA of the present invention on inflammatory cytokines induced by P. gingivalis LPS. A. TNF-α mRNA expression, B. IL-8 mRNA expression, C. TNF-α production, D. IL-8 production. [Figure 10] Graph showing the effect of S. salivarius G7 (Accession No. KCCM13161P) LTA of the present invention on inflammatory cytokines induced by T. forsythia LPS. A. TNF-α mRNA expression, B. IL-8 mRNA expression, C. TNF-α production, D. IL-8 production. [Figure 11] Graphs showing the effect of S. salivarius G7 (Accession No. KCCM13161P) LTA of the present invention on inflammatory cytokines induced by F. alocis LTA. A. TNF-α mRNA expression, B. IL-8 mRNA expression, C. TNF-α production, D. IL-8 production [Figure 12] 1 shows the results of flow cytometry analysis showing the ability of the S. salivarius G7 (Accession No. CCM13161P) LTA of the present invention to inhibit cell adhesion to LPS and LTA. AP gingivalis LPS binding, B forsythia LPS binding, C Falocis LTA binding. [Figure 13] 1 is a graph showing the ability of the S. salivarius G7 (accession number KCCM13161P) LTA of the present invention to inhibit adhesion of periodontitis-related bacterial substances CD14 and LBP. A, B: CP gingivalis, T. forsythia, and F. alocis CD14 adhesion inhibition; D: EF P gingivalis, T. forsythia, and F. alocis LBP adhesion inhibition. [Figure 14] 1 is a graph showing the effect of the culture solution of S. salivarius G7 (accession number KCCM13161P) of the present invention on the concentrations of volatile sulfur compounds H2S and CH3SH derived from P. gingivalis. [Figure 15]1 is a graph showing the effect of the S. salivarius G7 (deposit number KCCM13161P) strain of the present invention on the concentrations of volatile sulfur compounds H2S and CH3SH derived from P. gingivalis. [Figure 16] 3D confocal laser microscope images of cariogenic biofilms treated with and without S. salivarius G7 (accession number KCCM13161P) of the present invention (green indicates live bacteria, red indicates dead bacteria). [Figure 17] 1 is a graph showing the total number of bacteria, and the number of S. mutans and S. salivarius G7 bacteria in a cariogenic biofilm depending on the treatment concentration of S. salivarius G7 (accession number KCCM13161P) of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0047] Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. The contents described herein are provided to fully convey the concept of the present invention.
[0048] Example 1. Preparation of Streptococcus salivarius strains
[0049] The Streptococcus salivarius G7 of the present invention (deposit number KCCM13161P) was isolated, identified and characterized from a subgingival sample of a healthy Korean male and registered in the Korean Collection for Oral Microbiology (KCOM) (Streptococcus salivarius KCOM 2137). It was confirmed that the strain is particularly superior to conventional Streptococcus salivarius in terms of antibacterial, anti-inflammatory, caries inhibitory and halitosis inhibitory activities, and was deposited as a patent with the Korea Microorganisms Preservation Center (Korea Seed Bacteria Association) (deposit number: KCCM1316P, deposit date: 2023.04.21.).
[0050] The 16S rRNA sequence (SEQ ID NO: 1) of Streptococcus salivarius G7 of the present invention (deposition number KCCM13161P) is shown in FIG. 1. Based on this, phylogenetic analysis was carried out, and the results are shown in FIG.
[0051] As a comparison strain, Streptococcus salivarius K12 was isolated and identified from a commercially available product, and Streptococcus salivarius ATCC7073 (type strain) was purchased from the American Type Culture Collection (ATCC) and used.
[0052] <Example 2. Antibacterial and antifungal activity evaluation>
[0053] 2.1 Bacterial culture
[0054] The oral bacteria used for the antibacterial test of the strains were 12 kinds of microorganisms, consisting of oral disease-related gram-positive and gram-negative bacteria, representative antibacterial test strains, and fungi, as shown in Table 1. As for the dental caries-related bacteria, Streptococcus mutans ATCC25175 and S. sobrinus ATCC27607 were cultured in trypticase soy broth (TSB; BD bioscience, San Jose, CA, USA), and Actinomyces naeslundii ATCC 12104 was cultured in brain heart infusion (BHI; BD bioscience) liquid medium. Gingival and periodontal disease-related bacteria Actinomyces israelii (ATCC 12102) and Aggregatibacter actinomycetemcomitans (ATCC 43718) were cultured using Brain Heart Infusion (BD bioscience), while Fusobacterium nucleatum (ATCC 25586), Porphyromonas gingivalis (ATCC 33277), Prevotella intermedia (ATCC 25611), and Prevotella nigrescens (ATCC 33563) were cultured using BHI liquid medium supplemented with hemin (1 μg / ml) and vitamin K (0.2 μg / ml) under anaerobic conditions (25% H, 10% CO, 85% N) at 37°C. Enterococcus faecalis (ATCC 29212), a bacterium associated with apicoblastic periodontitis, was cultured in BHI liquid medium at 37°C under anaerobic conditions (25% H, 10% CO, 85% N). The fungus Candida albicans (ATCC10231) was cultured in TSB under aerobic conditions. Streptococcus pyogenes (ATCC12344) and S. pneumoniae (ATCC49416), bacteria associated with upper respiratory tract disease, were cultured in Todd Hewitt broth (BD bioscience) under aerobic conditions.Finally, representative gram-positive and gram-negative bacteria, Staphylococcus aureus (ATCC 23235) and Escherichia coli (ATCC 53868), were cultured under aerobic conditions using TSB. S. salivarius G7 (accession number KCCM13161P) of the present invention was cultured using M17 (BD bioscience) liquid medium.
[0055] [Table 1]
[0056] 2.2 Antibacterial activity test
[0057] The antibacterial activity test was performed using the method recommended by the Clinical & Laboratory Standard Institute. Bacteria cultured in liquid medium were centrifuged at 4,000 × g for 5 minutes, and clean liquid medium was added to measure the amount of bacteria using a bacterial counting chamber. Anaerobic bacteria were counted at 1.5 × 10 using clean medium in the measured bacterial suspension. 6 cell / ml, aerobic and facultative anaerobic bacteria were 1.0×10 6 The culture was adjusted to cells / ml and used in the experiment.
[0058] 180 μl of each medium was placed in a 96-well plate, and 20 μl of the G7 (accession number KCCM13161P) of the present invention, S. salivarius K12, and S. salivarius ATCC7073 prepared in the first row were placed in each well, and then serially diluted 2-fold and cultured in an anaerobic incubator for 24 or 36 hours. The bacterial growth was then analyzed by measuring the absorbance at 660 nm using a spectrophotometer, and the results are shown in Figures 3 to 6.
[0059] As shown in FIG. 3, the S. salivarius G7 (Accession No. KCCM13161P) of the present invention exhibited superior antibacterial activity against gingivitis-inducing bacteria A. actinomycetemcomitans, A. israelii, A. naeslundii, and apical inflammation-inducing bacteria E. faecalis, as compared with well-known S. salivarius strains S. salivarius ATCC7073 (type strain) or S. salivarius K12. A. actinomycetemcomitans causes gingivitis and may induce periodontitis in adolescents. It was observed that the growth of S. salivarius G7 (Accession No. KCCM13161P) of the present invention was inhibited in a culture medium in which A. actinomycetemcomitans was diluted 16-fold, and completely inhibited the growth of A. actinomycetemcomitans in a culture medium in which A. actinomycetemcomitans was diluted 8-fold. It was also observed that A. israelii was inhibited in the culture medium diluted 8 times, and completely inhibited in the culture medium diluted 4 times. It was also observed that A. naeslundii was inhibited in the culture medium diluted 8 times, and completely inhibited in the culture medium diluted 4 times. It was observed that E. faecalis was significantly inhibited in the culture medium diluted 16 times, and completely inhibited in the culture medium diluted 8 times. These results suggest that it has an antibacterial activity 8 times higher than that of conventional strains.
[0060] As shown in FIG. 4, the S. salivarius G7 (Accession No. KCCM13161P) of the present invention exhibited superior antibacterial activity against periodontitis-inducing bacteria F. nucleatum, P. gingivalis, P. intermedia, and P. nigrescens, as compared with well-known S. salivarius strains S. salivarius ATCC7073 (type strain) and S. salivarius K12. It was observed that S. salivarius G7 (Accession No. KCCM13161P) significantly inhibited the growth of F. nucleatum, P. gingivalis, P. intermedia, and P. nigrescens in a culture medium diluted 16-fold, and completely inhibited the growth in a culture medium diluted 8-fold. These results suggest that the antibacterial activity is 8 times or more stronger than that of conventional strains.
[0061] As shown in FIG. 5, the S. salivarius G7 (Accession No. KCCM13161P) of the present invention exhibited superior antibacterial activity against dental caries-inducing bacteria A. viscosus, S. mutans, and S. sobrinus, and upper respiratory tract disease-inducing bacteria S. pneumoniae and S. pyogenes, as compared with well-known S. salivarius strains S. salivarius ATCC7073 (type strain) and S. salivarius K12. It was observed that S. salivarius G7 (Accession No. KCCM13161P) significantly inhibited the growth of A. viscosus, S. mutans, and S. sobrinus, as well as S. pneumoniae and S. pyogenes, in a culture medium diluted 16-fold, and completely inhibited the growth of A. viscosus, S. mutans, and S. sobrinus, as well as S. pneumoniae and S. pyogenes, in a culture medium diluted 8-fold. These results suggest that the antibacterial activity is 8 times or more stronger than that of conventional strains.
[0062] As shown in FIG. 6, the S. salivarius G7 (Accession No. KCCM13161P) of the present invention exhibited superior antibacterial activity against the representative Gram-negative pathogen E. coli and the Gram-positive pathogen S. aureus, as compared with the well-known S. salivarius strains S. salivarius ATCC7073 (type strain) and S. salivarius K12. It was observed that S. salivarius G7 (Accession No. KCCM13161P) significantly inhibited the growth of E. coli and S. aureus in a culture medium diluted 8 times, and completely inhibited the growth of E. coli and S. aureus in a culture medium diluted 4 times. These results suggest that the antibacterial activity is 4 times or more stronger than that of the conventional strains.
[0063] 2.3 Antifungal activity test
[0064] An antifungal activity test against oral candidiasis-inducing fungus C. albicans was carried out in the same manner as in the antibacterial test, and the results are shown in FIG.
[0065] As shown in Figure 7, the S. salivarius G7 (Accession No. KCCM13161P) of the present invention exhibited superior antifungal activity against C. albicans compared to the well-known S. salivarius strains S. salivarius ATCC7073 (type strain) and S. salivarius K12. It was observed that S. salivarius G7 (Accession No. KCCM13161P) significantly inhibited the growth of C. albicans in a culture medium diluted 8-fold, and completely inhibited the growth in a culture medium diluted 4-fold. These results suggest that it has an antibacterial activity 4-fold or more higher than that of the conventional strains.
[0066] Example 3: Evaluation of anti-inflammatory activity
[0067] The inflammation-suppressing effect of S. salivarius G7 (Accession No. KCCM13161P) of the present invention was confirmed using gingival fibroblasts. As the inflammation-inducing substances, Porpyromonas gingivalis-derived LPS (lipopolysaccharide), Tannerella forsythia-derived LPS (lipopolysaccharide), or Filifactor alocis-derived LTA (lipoteichoic acid) was used as shown in Table 2 below.
[0068] [Table 2]
[0069] P. gingivalis LPS, T. forsythia LPS, and F. alocis LTA each bind to TLR4 and TLR2 on the cell membranes of oral cavity, initiating signal transduction and inducing inflammation. CD14 and LBP (Lipopolysaccharide-binding Protein) are required for LPS or LTA to attach to TLR4 and TLR2. S. salivarius LTA competitively inhibits the attachment of LPS and LTA of periodontitis bacteria to CD14 and LBP, preventing them from attaching to TLR, thereby suppressing the inflammation-inducing activity of LPS and LTA.
[0070] Gingival fibroblast cell line HGF-1 was inoculated into a 12-well polystyrene plate and cultured until it was filled to about 80%, after which the medium was removed and 1 ml of DMEM medium supplemented with 2% human serum (Sigma-Aldrich Co., San Jose, CA, USA) and penicillin / streptomycin (Hyclone) was added. Then, S. salivarius G7 of the present invention (accession number KCCM13161P) was disrupted using an ultrasonic device, the resulting cell lysate was treated, and 100 μg of LPS or LPA, an inflammatory inducer, was mixed and cultured for 12 hours. The culture medium was then analyzed for TNF-α and IL-8 using an ELISA kit. In addition, total RNA was extracted from the cells using TRIzol (Invitrogen, Carlsbad, CA), and the purity and concentration of the extracted RNA was measured using Nanodrop (Invitrogen). 1 μg of total RNA was used to synthesize cDNA using Maxime RT premix (Intron Biotech., Gyeonggi), and inflammation-related cytokines were investigated using a real-time gene amplifier (AB7500 Real-time PCR instrument system; Applied biosystems), and the results are shown in Figures 8 to 11. The primer information for the inflammatory cytokines used in this experiment is shown in Table 3 below.
[0071] [Table 3]
[0072] Fig. 8 shows the virulence of cell lysates containing cell surface substances of S. salivarius G7 (Accession No. KCCM13161P) of the present invention. Human gingival fibroblast cell line HGF-1 was treated with lipopolysaccharide derived from Escherichia coli (Ec LPS), lipoteichoic acid derived from S. salivarius type strain (ATCC7073) (Ss type LTA), surface protein derived from S. salivarius type strain (ATCC7073) (Ss type SP), LTA derived from S. salivarius G7 (Accession No. KCCM13161P) of the present invention (SS G7LTA), and SP derived from S. salivarius G7 (Accession No. KCCM13161P) of the present invention (SS G7SP), and the amounts of mRNA and protein produced for TNF-α and IL-8 are shown in Fig. 8. As shown in Figure 8, the mRNA and protein production of TNF-α and IL-8 increased only upon treatment with E. coli-derived LPS (Ec LPS), confirming that LTA or SP of S. salivarius does not act as virulence factors.
[0073] 9 is a graph showing the effect of the S. salivarius G7 (Accession No. KCCM13161P) LTA of the present invention on inflammatory cytokines induced by P. gingivalis LPS. As shown in FIG. 9, when the gingival fibroblast cell line HGF-1 was treated with P. gingivalis LPS (Pg LPS), the amount of mRNA and protein produced for TNF-α and IL-8 increased, and when the S. salivarius type strain was treated with the S. salivarius G7 (Accession No. KCCM13161P) LTA of the present invention, the amount of mRNA and protein produced for TNF-α and IL-8 was suppressed. In particular, it was confirmed that the S. salivarius G7 (Accession No. KCCM13161P) LTA of the present invention significantly suppressed the amount of mRNA and protein produced for TNF-α and IL-8 compared to the S. salivarius type strain.
[0074] 10 is a graph showing the effect of the S. salivarius G7 (Accession No. KCCM13161P) LTA of the present invention on inflammatory cytokines induced by T. forsythia LPS. As shown in FIG. 10, when the gingival fibroblast cell line HGF-1 was treated with T. forsythia LPS (Tf LPS), the amount of mRNA and protein produced for TNF-α and IL-8 increased, and when the S. salivarius type strain was treated with the S. salivarius G7 (Accession No. KCCM13161P) LTA of the present invention, the amount of mRNA and protein produced for TNF-α and IL-8 was suppressed. In particular, it was confirmed that the S. salivarius G7 (Accession No. KCCM13161P) LTA of the present invention significantly suppressed the amount of mRNA and protein produced for TNF-α and IL-8 compared to the S. salivarius type strain.
[0075] 11 is a graph showing the effect of the S. salivarius G7 (Accession No. KCCM13161P) LTA of the present invention on inflammatory cytokines induced by F. alocis LTA. As shown in FIG. 11, when the gingival fibroblast cell line HGF-1 was treated with F. alocis LTA (FaLTA), the amount of mRNA and protein produced for TNF-α and IL-8 increased, and when the S. salivarius type strain was treated with the S. salivarius G7 (Accession No. KCCM13161P) LTA of the present invention, the amount of mRNA and protein produced for TNF-α and IL-8 was suppressed. In particular, it was confirmed that the S. salivarius G7 (Accession No. KCCM13161P) LTA of the present invention significantly suppressed the amount of mRNA and protein produced for TNF-α and IL-8 compared to the S. salivarius type strain.
[0076] From the above results, it was confirmed that S. salivarius G7 of the present invention (accession number KCCM13161P) can suppress inflammation induced by periodontitis-inducing bacteria.
[0077] Example 4: Evaluation of the ability of periodontitis-related bacteria to inhibit cell adhesion
[0078] 4.1 Flow cell analysis
[0079] Based on the above results, we evaluated whether the S. salivarius G7 (Accession No. KCCM13161P) LTA of the present invention can inhibit the attachment of LPS or LTA derived from periodontitis-inducing bacteria to cells. After fluorescent substances were attached to P. gingivalis LPS, T. forsythia LPS, and F. alocis LTA, human gingival fibroblast cell line HGF-1 was treated with LTA (Ss type LTA) derived from S. salivarius type strain (ATCC7073) or S. salivarius G7 (Accession No. KCCM13161P) LTA of the present invention and cultured, and the degree of fluorescence of the cells was confirmed by flow cytometry and is shown in Figure 12.
[0080] LPS (1 mg) derived from P. gingivalis and T. forsythia and LTA derived from F. alocis were reacted with cold sodium metaperiodate at 4°C for 30 minutes, and the reaction solution was placed in a standard RC dialysis membrane tubing (Spectrum Laboratories Inc., Ranch Dominaquez, CA, USA) and dialyzed against 100 mM sodium acetate (pH 5.5) for 12 hours. The solution containing LPS and LTA was mixed with 10 mM Alexa FluorTM-488 hydrazide (Invitrogen, Carlsbad, CA, USA) prepared by dissolving in 200 mM KCl, and left at room temperature for 6 hours in coupling buffer (0.1 M sodium phosphate, 0.15 M NaCl, pH 7.2), and dialyzed three times for 12 hours against 1 L of endotoxin-free water. The fluorescently labeled LPS and LTA were then transferred to a new tube and stored at -20°C.
[0081] Then, the Alexa Fluor™ 488-labeled LPS or LTA was treated with THP-1 cell line, a human mononuclear cell line, for 1 hour at 37°C in the presence or absence of various concentrations of S. salivarius G7 surface extract. The cells were then centrifuged at 500xg for 3 minutes in a CO2 incubator and washed three times with cold DPBS (Dulbecco's phosphate buffered saline, pH 7.2). The binding of Alexa 488-labeled LPS and LTA to the cells was then analyzed by flow cytometry (FACS calibur, BD biosciences, Sparks, MD, USA). 10,000 cells were counted and data was collected, and the binding of Alexa Fluor™ 488-labeled LPS and LTA was detected from the FL-1 channel, and the data was analyzed using CellQuest software (BD biosciences).
[0082] As shown in Fig. 12, the number of fluorescent cells, i.e., cells to which LPS and LTA were attached, increased significantly by treatment with P. gingivalis LPS, T. forsythia LPS, and F. alocis LTA, and the number of fluorescent cells decreased significantly when co-cultured with LTA derived from S. salivarius type strain (ATCC7073) (Ss type LTA) or the LTA of S. salivarius G7 (Accession No. KCCM13161P) of the present invention. In particular, it was confirmed that the LTA of S. salivarius G7 (Accession No. KCCM13161P) of the present invention significantly reduced the number of cells to which LPS and LTA were attached, compared to S. salivarius type strain.
[0083] 4.2 CD14 and LBP adhesion inhibition assay
[0084] In order for the P. gingivalis LPS, T. forsythia LPS, and F. alocis LTA to induce inflammatory cytokines through TLR4 and TLR2, respectively, the LPS and LTA must first bind to CD14 and LBP on the oral cell membrane. We confirmed whether S. salivarius LTA competitively inhibits the adhesion of periodontal bacteria LPS and LTA to CD14 and LBP.
[0085] Fluorescently conjugated P. gingivalis LPS, T. forsythia LPS, or F. alocis LTA was cultured with CD14 or LBP protein in the presence of various concentrations of LTA (Ss type LTA) derived from S. salivarius type strain (ATCC7073) or LTA from S. salivarius G7 (accession number KCCM13161P) of the present invention, and the degree of adhesion was measured. The results are shown in Figure 13.
[0086] Anti-LBP mAb (MAB870, R&D systems, Minneapolis, MN, USA) and anti-CD14 Ab (AF982, R&D systems) were dissolved in DPBS at a concentration of 1 μg / ml, and the antibodies (50 ng / well) were dispensed into EIA plates (Corning Co., Corning, NY, USA) and coated at 4°C for 12 hours. The antibody-coated EIA plate was washed five times with phosphate buffered saline (PBST) containing 0.1% Tween 20, and DPBST containing 1% bovine serum albumin (BSA) was dispensed and inactivated under weak shaking conditions for 2 hours. Then, recombinant human LBP (rhLBP, R&D systems) and human CD14 (rhCD14, R&D systems) were dissolved in DPBS at a concentration of 2 μg / ml and added to the wells of the antibody-coated EIA plate. After the plate was left at room temperature for 4 hours and washed five times with PBST, biotin-labeled LPS or LTA was added to wells prepared separately or in combination with S. salivarius LTA and left at room temperature for 2 hours. To measure the binding of biotin-labeled LPS and LTA to rhLBP and rhCD14, the plate was reacted with 50 μl of HRP-labeled streptavidin (1 μg / ml) in PBST containing 2% BSA for 1 hour. After washing five times with PBST, 3,3',5,5'-tetramethylbenzidine (TMB) solution was added to the wells and left at room temperature for 30 minutes, and the enzyme reaction was stopped with 1N sulfuric acid. The absorbance was measured at 450 nm wavelength using a microplate reader (Biotek, Winooski, VT, USA).
[0087] As shown in Fig. 13, the binding of P. gingivalis LPS, T. forsythia LPS, or F. alocis LTA to CD14 or LBP decreased with increasing concentration of LTA derived from S. salivarius type strain (ATCC7073) (Ss type LTA) or S. salivarius G7 (accession number KCCM13161P) of the present invention. In particular, it was confirmed that LTA from S. salivarius G7 (accession number KCCM13161P) of the present invention significantly inhibited the binding of LPS or LTA to CD14 or LBP compared to S. salivarius type strain.
[0088] Example 5: Evaluation of volatile sulfur compound suppression ability
[0089] In order to confirm whether the S. salivarius G7 (accession number KCCM13161P) of the present invention has an effect of suppressing bad breath, an experiment was carried out using a culture medium of P. gingivalis, which produces volatile yellow compounds. 8 After culturing for 48 hours, 300 μl of the bacterial culture was transferred to a clean 50-ml circular tube, and then 300 μl or 600 μl of the S. salivarius G7 (accession number KCCM13161P) culture of the present invention or 10 live bacteria were added to the circular tube containing the P. gingivalis culture. 7 or 10 8 The cells were placed in the tube, and the medium was added to a final volume of 5 ml. The tube was then shaken for 1 minute using a vertical shaker and left at room temperature for 5 minutes. Then, 1 ml of air was collected from directly above the solution surface using a 1 ml syringe, and the concentrations of hydrogen sulfide (HS) and methyl sulfide (CHSH) were measured using gas chromatography (OralchromaTM; Nissha FIS, Inc., Osaka, Japan). The results are shown in Figures 14 and 15.
[0090] As shown in FIG. 14, the S. salivarius G7 (accession number KCCM13161P) culture solution of the present invention reduced the concentrations of hydrogen sulfide (HS) and methyl sulfide (CHSH), which are volatile sulfur compounds that induce halitosis, in a concentration-dependent manner in the P. gingivalis culture solution.
[0091] In addition, as shown in FIG. 15, the S. salivarius G7 (deposition number KCCM13161P) strain of the present invention itself reduced the concentrations of hydrogen sulfide (H2S) and methyl sulfide (CH3SH) in a concentration-dependent manner.
[0092] From the above results, it was confirmed that S. salivarius G7 (accession number KCCM13161P) of the present invention can effectively suppress the bad breath produced by P. gingivalis.
[0093] <Example 6. Evaluation of biofilm formation inhibition>
[0094] 6.1 Biofilm formation inhibitory effect
[0095] The present invention was evaluated for its ability to substantially inhibit biofilm formation. Saliva from 10 adults without periodontitis was collected and mixed, then the mixture was placed in two tubes. First, to prepare a saliva-coated plate, an equal amount of phosphate buffer solution was placed in one of the tubes, centrifuged at 4°C and 6,000 x g for 10 minutes, and the supernatant was transferred to a clean tube. Saliva bacteria were prepared by adding an equal amount of BHI medium to the saliva mixture in the other tube, centrifuging it at 2,000 x g for 10 minutes, and transferring the supernatant to a clean tube.
[0096] The saliva for coating was dispensed in an amount of 200 μl into an 8-well glass plate and dried in an oven at 40° C. This process was repeated 10 times. The saliva-coated plate prepared above was sterilized in a UV sterilizer. Then, 100 μl of S. mutans (1×10) was added to 10 ml of saliva bacterial suspension containing 2% sucrose to form a cariogenic biofilm.8 After adding 1000 μl of the S. salivarius G7 (accession number KCCM13161P) of the present invention to BHI containing 2% sucrose, the control group was cultured for 7 days while changing the medium every day. 7 and 10 8 The 8-well plates were inoculated at two concentrations to contain the number of strains and cultured for 7 days while changing the medium. To examine the amount of biofilm, the 8-well plates were then stained with a Bacterial live / dead staining kit (Invitrogen) and observed in 3D using a confocal laser microscope, as shown in Figure 16.
[0097] As shown in FIG. 16, salivary strains and S. mutans formed a complex biofilm on the saliva-coated plate, and when the S. salivarius G7 of the present invention (accession number KCCM13161P) was added to the biofilm, the number of killed biofilm-forming strains increased and the biofilm loosened.
[0098] 6.2 Measurement of bacterial count in biofilm
[0099] The total number of bacteria (Oral streptococci), S. mutans and S. salivarius G7 (Accession No. KCCM13161P) in the formed biofilm was measured. 1 ml of DPBS was added to the 12-well plate to physically remove the cultured biofilm. This was centrifuged at 5,000×g for 1 minute to obtain a bacterial precipitate, and total DNA was extracted from the bacterial precipitate using a G-spin genomic DNA extraction kit (iNtRON Biotechnology, Gyeonggi, Korea), and the bacteria were quantified using a real-time gene amplifier.
[0100] Real-time gene analysis was performed with the standard quantitative DNA and the samples. TB green premix (Takara Co., Tokyo, Japan), ROX II dye, primers and DNA were mixed and pre-heated at 94°C for 5 minutes, followed by 40 cycles of denaturation stage at 95°C for 10 seconds, annealing stage at 60°C for 10 seconds and extension stage at 72°C for 33 seconds. A product dissolution curve was used to examine non-specific binding. A standard curve of Ct value and bacterial amount was created using standard DNA, and the number of bacteria was calculated using the Ct value of the sample DNA based on this, and the results are shown in Figure 17. The primers used are shown in Table 4.
[0101] [Table 4]
[0102] As shown in FIG. 17, the amount of S. salivarius G7 (accession number KCCM13161P) in the biofilm increased as the amount of treatment increased, but it was confirmed that S. mutans, a causative bacterium of dental caries, significantly decreased as the amount of treatment with S. salivarius G7 (accession number KCCM13161P) of the present invention increased. [Accession number]
[0103] Depository institution: Korea Center for Culture Collection of Microorganisms (KCCM) Accession number: KCCM13161P Entrustment date: April 21, 2022
Claims
1. An antibacterial composition for inhibiting oral bacteria, comprising a Streptococcus salivarius G7, deposit number: KCCM13161P strain, The antibacterial activity of the antibacterial agent is effective against Aggregatibacter actinomycescomitans, Actinomyces israelii, Actinomyces naeslundii, Enterococcus faecalis, Fusobacterium nucleatum, Porphyromonas gingivalis, Prevotella intermedia, Bacteroides intermedius, Prevotella nigrescens, Actinomyces viscosus, Escherichia coli, and Staphylococcus aureus. A strain characterized by the above.
2. Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain or a culture thereof A pharmaceutical composition for treating or ameliorating oral candidiasis.
3. The pharmaceutical composition for treating or improving oral candidiasis has antifungal activity against Candida albicans. The pharmaceutical composition for treating or ameliorating oral candidiasis according to claim 2.
4. Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain or a culture thereof. A composition for suppressing bad breath.
5. The suppression of bad breath is achieved by suppressing the concentrations of hydrogen sulfide (H 2 S) and methyl sulfide (CH 3 SH). The composition for suppressing bad breath according to claim 4.
6. The composition for suppressing bad breath is manufactured into one product selected from the group consisting of toothpaste, mouthwash, gum, candy, caramel, jellies, mouth spray, oral ointment, mouthwash, oral cleaning agent, and tooth whitening agent. The composition for suppressing bad breath according to claim 4.
Citation Information
Patent Citations
antibacterial composition
JP2005517439A
NOVEL STRAIN OF Lactobacillus plantarum AND COMPOSITION FOR PREVENTING OR TREATING OF INFLAMMATORY DISEASE USING THE SAME
KR1020220139280A
Composition comprising superoxide dismutase and / or bacillus strain spores, and uses thereof for improving oral health
KR1020230017372A
